SA Journal of Diabetes & Vascular Disease: Vol 4, Issue 1, March 2007

BUY / PURCHASE / PAY ONLINE • SEARCH • SUBMIT MANUSCRIPT • EDITORIAL MANAGER LOGIN • SABINET LOGIN

Home
Contact

SAJDVD: VOLUME 4, ISSUE 1, MARCH 2007

Title: Incretins - from effect to therapy : editorial
Authors: Wing, Jeff
From: South African Journal of Diabetes and Vascular Disease, Vol 4, Issue 1, Mar
Published: 2007
Pages: 4-5
Full text: Click here to order
Full text: Click here to read online (Login Required)
Title: Unlikely bedfellows? Management of diabetes and cardiovascular disease : the new ESC-EASD joint guidelines : editorial
Authors: Distiller, Larry A.
From: South African Journal of Diabetes and Vascular Disease, Vol 4, Issue 1, Mar
Published: 2007
Pages: 6-7
Full text: Click here to order
Full text: Click here to read online (Login Required)
Title: Non-alcoholic fatty liver disease : natural history, pathogenesis and treatment : review
Authors: Hayes, Peter C.; Campbell, Ian W.; Ferguson, James W.; Mcavoy, Norma C.
From: South African Journal of Diabetes and Vascular Disease, Vol 4, Issue 1, Mar
Published: 2007
Pages: 9-16
Full text: Click here to order
Full text: Click here to read online (Login Required)
Abstract: Non-alcoholic fatty liver disease (NAFLD) is the term used to describe the alcohol-like liver injury that occurs in the absence of alcohol abuse. It embraces a range of histological abnormalities including simple steatosis or fatty liver, non-alcoholic steatohepatitis (NASH) and NAFLD induced cirrhosis. The predominant risk factor for NAFLD appears to be insulin resistance. Simple steatosis and NASH are generally asymptomatic and it is only the development of cirrhosis that has clinical consequence. At present, therapy in NAFLD concentrates on managing risk factors but in the future clinical trials may provide robust evidence for the use of insulin sensitising agents and other potential therapies.
Title: Non-alcoholic fatty liver disease in childhood : review
Authors: Brown, Rachel; Baumann, Ulrich
From: South African Journal of Diabetes and Vascular Disease, Vol 4, Issue 1, Mar
Published: 2007
Pages: 18-22
Full text: Click here to order
Full text: Click here to read online (Login Required)
Abstract: Non-alcoholic fatty liver disease (NAFLD) is an often undiagnosed entity of chronic liver disease with an uncertain prognosis. Recently NAFLD has probably become the most frequent cause of chronic liver disease in children. The term NAFLD covers a spectrum of non-alcoholic fatty liver disease from benign static disease to more aggressive forms that can progress to cirrhosis within childhood. The term non-alcoholic steatohepatitis (NASH) is nowadays reserved to describe these progressive forms of NAFLD. Insulin resistance is a significant aetiological factor and hence a majority of patients with diabetes, obesity and the metabolic syndrome have the disease. Histological confirmation of NAFLD requires 5% steatosis to support the diagnosis and distinguishes an adult (NASH type 1) and a paediatric form (NASH type 2). Current treatment options focus on lifestyle changes to improve underlying obesity and glucose intolerance. This article provides an overview of currently existing data regarding diagnosis and management of children with suspected NAFLD.
Title: How oral glycaemic drugs work
Authors: Schachter, Michael
From: South African Journal of Diabetes and Vascular Disease, Vol 4, Issue 1, Mar
Published: 2007
Pages: 24-25
Full text: Click here to order
Full text: Click here to read online (Login Required)
Title: Severe mental illness, antipsychotic drugs and the metabolic syndrome : review
Authors: Holt, Richard I.G.
From: South African Journal of Diabetes and Vascular Disease, Vol 4, Issue 1, Mar
Published: 2007
Pages: 26-31
Full text: Click here to order
Full text: Click here to read online (Login Required)
Abstract: The prevalence of the metabolic syndrome is increased 2-3-fold among people with severe mental illness (SMI) and may explain the high risk of cardiovascular disease in this patient group. The reason for the increase in the metabolic syndrome in people with SMI is unclear but is likely to be multifactorial, including both hereditary and environmental factors. There are concerns that antipsychotic medication may be responsible for the increased prevalence of diabetes, the metabolic syndrome and cardiovascular disease in people with SMI. While the evidence linking the antipsychotics with diabetes remains inconclusive, certain antipsychotics, notably olanzapine and clozapine are associated with weight gain and hypertriglyceridaemia. At present there is little systematic monitoring of cardiovascular risk factors in people with SMI and consequently there is a high prevalence of undiagnosed metabolic problems. The burden of cardiovascular disease and diabetes could be reduced in people with SMI if lifestyle intervention was instituted and pharmacotherapy used when indicated. The adverse effects of antipsychotic medication should be balanced with the therapeutic benefits which may be important in ensuring that patients are able to make the necessary changes to reduce the burden of diabetes and cardiovascular disease.
Title: Aspirin in cardiovascular disease : the prons and cons : therapeutics review
Authors: Kirby, Mike
From: South African Journal of Diabetes and Vascular Disease, Vol 4, Issue 1, Mar
Published: 2007
Pages: 32-34
Full text: Click here to order
Full text: Click here to read online (Login Required)
Title: Diabetes in pregnancy : future CVD patients in waiting? : disease focus
Authors: Mayor, Susan
From: South African Journal of Diabetes and Vascular Disease, Vol 4, Issue 1, Mar
Published: 2007
Pages: 35-37
Full text: Click here to order
Full text: Click here to read online (Login Required)
Title: Nutrition in the management of type 2 diabetes mellitus : carbohydrates : achieving best practice
Authors: Shand, Lesley
From: South African Journal of Diabetes and Vascular Disease, Vol 4, Issue 1, Mar
Published: 2007
Pages: 38-39
Full text: Click here to order
Full text: Click here to read online (Login Required)
Title: Individualising glucose-lowering therapies in type 2 diabetes : drug trends in diabetes
Authors: Abrahamson, Martin
From: South African Journal of Diabetes and Vascular Disease, Vol 4, Issue 1, Mar
Published: 2007
Pages: 40, 42
Full text: Click here to order
Full text: Click here to read online (Login Required)
Title: Realising the value of modern insulin in type 2 diabetes : drug trends in diabetes
From: South African Journal of Diabetes and Vascular Disease, Vol 4, Issue 1, Mar
Published: 2007
Pages: 43-44
Full text: Click here to order
Full text: Click here to read online (Login Required)
Title: Rimonabant offers intriguing opportunities in early type 2 diabetes management : drug trends in diabetes
From: South African Journal of Diabetes and Vascular Disease, Vol 4, Issue 1, Mar
Published: 2007
Pages: 45, 48
Full text: Click here to order
Full text: Click here to read online (Login Required)

LATEST EDITORS' CHOICE

Interesting features, including:

RELIABLE EXPERT INFORMATION

The SAJDVD’s main focus is providing new and relevant information for doctors, nurses and allied professionals involved in caring for the diabetes patient.

But as we are part of the larger Diabetes team, we would like to reach out to all patients with relevant information. So here it is!